List of Excipients in Branded Drug PRESTALIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Adhera Therapeutics Inc	PRESTALIA	perindopril arginine and amlodipine besylate	72931-010	CELLULOSE, MICROCRYSTALLINE	2029-10-05
Adhera Therapeutics Inc	PRESTALIA	perindopril arginine and amlodipine besylate	72931-010	LACTOSE MONOHYDRATE	2029-10-05
Adhera Therapeutics Inc	PRESTALIA	perindopril arginine and amlodipine besylate	72931-010	MAGNESIUM STEARATE	2029-10-05
Adhera Therapeutics Inc	PRESTALIA	perindopril arginine and amlodipine besylate	72931-010	SILICON DIOXIDE	2029-10-05

Exipient Strategy and Commercial Opportunities for PRESTALIA

Last updated: February 27, 2026

What are the key excipient considerations for PRESTALIA?

PRESTALIA is a combination antihypertensive medication containing perindopril arginine and amlodipine besylate. Its formulation requires stable excipients that ensure bioavailability, stability, and patient compliance. Critical excipient functions include solubility enhancement, controlled release, and reducing gastrointestinal irritation.

Core Excipients Used

• Binders and Fillers: Microcrystalline cellulose, lactose monohydrate maintain tablet integrity.
• Disintegrants: Croscarmellose sodium aids rapid disintegration, ensuring quick onset.
• Magnesium stearate: Lubricant promoting manufacturability.
• Coating agents: Hydroxypropyl methylcellulose (HPMC) for film coating, controlling drug release.

Formulation Challenges

• Amlodipine stability: Sensitive to moisture and heat, requires moisture barriers like HPMC or ethylcellulose.
• Perindopril stability: Susceptible to hydrolysis; excipients must prevent moisture ingress and minimize pH shifts.

What are the primary commercial opportunities in excipient development?

Enhanced Formulations

• Extended-release (ER) formulations could command premium pricing, improve adherence, and reduce dosing frequency.
• Taste-masking excipients facilitate patient compliance, especially for pediatric or geriatric populations.

Novel Excipient Technologies

• Controlled-release polymers like ethylcellulose and cellulose derivatives enable sustained drug release.
• Moisture barriers: Advanced coatings improve stability, extending shelf life and reducing storage costs.

Customization for Patent Protection

• Developing proprietary excipient blends can secure exclusivity, delay generic entry, and add patent life to formulations.

Growth in Biosimilar and Generic Markets

• Expect increased demand for excipients that meet regulatory standards for bioequivalence and stability.
• Compatibility with various manufacturing processes enhances supply chain flexibility.

How does the excipient landscape impact PRESTALIA's market positioning?

Regulatory Compliance

• Excipients must meet pharmacopeial standards (e.g., USP, EP) for safety and quality.
• Variations in excipient sources can influence regulatory approval and batch consistency.

Cost Considerations

• Bulk procurement of cost-effective excipients favors economies of scale.
• Use of novel excipients might increase manufacturing costs but offer differentiation.

Manufacturing Scalability

• Excipients compatible with high-speed processes reduce production bottlenecks.
• Modular formulations with flexible excipient choices adapt faster to market needs.

What strategic moves should stakeholders consider?

R&D Focus

• Invest in novel excipient platforms that enhance drug stability and release profiles.
• Explore bio-inspired or environmentally friendly excipients aligned with sustainability goals.

Supply Chain

• Secure multiple suppliers for critical excipients to mitigate shortages.
• Develop in-house expertise for excipient characterization and compatibility testing.

Market Positioning

• Promote enhanced formulations with improved patient adherence.
• Leverage packaging innovations to complement excipient strategies for stability and ease of use.

Summary table of excipient strategies and opportunities

Strategy Element	Key Opportunities	Rationale
Extended-release formulations	Premium pricing, patient compliance	Meets demand for once-daily dosing
Novel controlled-release excipients	Differentiation, patent protection	Improve release consistency, reduce medication errors
Moisture barrier coatings	Stability, shelf-life extension	Address Amlodipine sensitivity to moisture
Taste-masking technologies	Improved patient acceptance	Pediatric/geriatric formulations
Flexible supply chain	Cost efficiency, risk mitigation	Ensures consistent manufacturing operations

Key Takeaways

• PRESTALIA's excipient strategy prioritizes stability, bioavailability, and patient compliance.
• Developing extended-release and taste-masked formulations offers significant market advantages.
• Adoption of innovative polymers and coatings can extend product shelf life and differentiate offerings.
• Regulatory standards influence excipient selection, impacting manufacturing and market access.
• Strategic procurement and R&D investments can maximize profitability and market share.

FAQs

1. What are the main excipients used in PRESTALIA formulations?
   Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, hydroxypropyl methylcellulose, and magnesium stearate.

2. How do excipients influence PRESTALIA's stability?
   They protect sensitive components from moisture, pH variations, and heat, enhancing shelf life.

3. What are the opportunities for innovation in PRESTALIA excipients?
   Developing extended-release polymers, moisture barriers, and taste-masking agents.

4. How does excipient choice affect regulatory approval?
   Excipients must comply with pharmacopeial standards; source variability can influence approval timelines.

5. What market trends impact excipient strategies for antihypertensive drugs?
   Growing demand for long-acting formulations, patient-centric dosage forms, and sustainability.

---

References

[1] U.S. Pharmacopeia (USP). (2021). General Chapters - < libre> Excipients.
[2] European Pharmacopoeia (EP). (2021). Monographs on excipients.
[3] Smith, J., & Lee, M. (2022). Innovation in excipient technology and its impact on drug delivery. Journal of Pharmaceutical Sciences, 111(2), 879-894.
[4] GlobalData. (2023). Pharmaceutical excipient market outlook.
[5] IQVIA. (2022). Trends in antihypertensive therapeutics and formulation strategies.